Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen Biotechnology's EBIT per Share for the
three
months ended in Dec. 2025 was NT$-1.19.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.40.
During the past 3 years, the average EBIT per Share Growth Rate was 60.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Medigen Biotechnology's EBIT per Share or its related term are showing as below:
ROCO:3176'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -141 Med: -11.05 Max: 60.1
Current: 60.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Medigen Biotechnology was 60.10% per year. The lowest was -141.00% per year. And the median was -11.05% per year.
ROCO:3176's 3-Year EBIT Growth Rate is ranked better than 90.62% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs ROCO:3176: 60.10
Medigen Biotechnology (ROCO:3176) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Medigen Biotechnology EBIT per Share Related Terms
Medigen Biotechnology EBIT per Share Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a EBIT per Share of NT$-1.40 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medigen Biotechnology and its competitors. According to the industry distribution chart, Medigen Biotechnology ranks #110 out of 1173 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Medigen Biotechnology's EBIT per Share too high?
Medigen Biotechnology's current EBIT per Share is NT$-1.40. Based on the distribution chart, Medigen Biotechnology ranks #110 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #110 out of 1173 companies for EBIT per Share. This places Medigen Biotechnology in the top 9% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medigen Biotechnology and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current EBIT per Share is NT$-1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$49.74, compared to a current price of NT$33.75 — trading 32.1% below its estimated fair value. The current EBIT per Share is NT$-1.40. Medigen Biotechnology's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current EBIT per Share is NT$-1.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$33.75 is trading 32.1% below its estimated GF Value™ of NT$49.74.
GuruFocus considers Medigen Biotechnology to be Significantly Undervalued.
Key valuation signals for ROCO:3176:
EBIT per Share: NT$-1.40
GF Value™: NT$49.74 vs. price of NT$33.75 (32.1% below fair value)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
